CIBC Asset Management Inc Buys 44,110 Shares of Amgen Inc. $AMGN

CIBC Asset Management Inc boosted its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 12.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 404,263 shares of the medical research company’s stock after acquiring an additional 44,110 shares during the quarter. CIBC Asset Management Inc’s holdings in Amgen were worth $132,319,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Anfield Capital Management LLC increased its stake in Amgen by 1,000.0% during the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after acquiring an additional 70 shares during the last quarter. Dogwood Wealth Management LLC increased its position in Amgen by 275.0% during the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 55 shares during the last quarter. Board of the Pension Protection Fund bought a new position in Amgen during the fourth quarter valued at $26,000. Manning & Napier Advisors LLC increased its position in Amgen by 49.2% during the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock valued at $32,000 after acquiring an additional 32 shares during the last quarter. Finally, Olistico Wealth LLC bought a new position in Amgen during the fourth quarter valued at $33,000. 76.50% of the stock is owned by institutional investors.

Insider Activity at Amgen

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the company’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the transaction, the senior vice president directly owned 7,009 shares in the company, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.85% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on AMGN. Royal Bank Of Canada boosted their price objective on shares of Amgen from $360.00 to $370.00 and gave the company an “outperform” rating in a research report on Tuesday, April 7th. Leerink Partners reiterated a “market perform” rating and set a $355.00 price objective on shares of Amgen in a research report on Thursday, March 5th. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Amgen from $285.00 to $295.00 and gave the company a “hold” rating in a research report on Thursday, February 5th. Guggenheim cut their target price on Amgen from $351.00 to $340.00 and set a “neutral” rating on the stock in a research note on Monday, May 4th. Finally, Argus cut their target price on Amgen from $400.00 to $375.00 and set a “buy” rating on the stock in a research note on Wednesday, May 20th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $355.19.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: The European Commission approved Amgen’s Imdylltra for extensive-stage small cell lung cancer after phase III data showed a 40% reduction in the risk of death, a meaningful catalyst that could boost future sales and investor sentiment. EC approval for Amgen’s Imdylltra
• Positive Sentiment: Multiple follow-up reports highlighted the same EU approval, reinforcing the market’s view that Amgen is adding a potentially important growth driver to its oncology portfolio. Amgen Secures EU Nod for Imdylltra in Lung Cancer Indication
• Neutral Sentiment: Zacks also pointed to Amgen as a strong momentum stock, which supports the bullish technical narrative but does not add a new business-specific catalyst. Here’s Why Amgen (AMGN) is a Strong Momentum Stock
• Neutral Sentiment: Analyst commentary on Amgen’s valuation suggests some upside remains, but it also notes that recent gains may already reflect much of the optimism, creating a more balanced long-term view. How The Amgen (AMGN) Story Is Evolving As Rare Disease Upside Meets Valuation Caution

Amgen Trading Down 0.3%

NASDAQ AMGN opened at $328.26 on Wednesday. The company’s 50-day moving average price is $342.12 and its 200-day moving average price is $345.42. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65. The stock has a market cap of $177.17 billion, a PE ratio of 22.84, a PEG ratio of 3.30 and a beta of 0.42. Amgen Inc. has a 12 month low of $267.83 and a 12 month high of $391.29.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. The firm had revenue of $8.62 billion for the quarter, compared to analysts’ expectations of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The business’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same period in the prior year, the business posted $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Equities research analysts forecast that Amgen Inc. will post 22.37 earnings per share for the current year.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.